Article Per Year (5 Year)
p-Index From 2021 - 2026
0.23
P-Index
This Author published in this journals
All Journal Pharmascience
Kumar, Punet
Unknown Affiliation
Medicine & Pharmacology

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Molecular Basis for the Enhanced CDK2 Inhibition by Artesunate: Superior Binding Affinity to the ATP-Catalytic Site Pratama, Mohammad Rizki Fadhil; Mulyani, Evi; Suratno, Suratno; Kumar, Punet; Tjahjono, Daryono Hadi; Kartawinata, Tutus Gusdinar
Journal of Pharmascience Vol 13, No 1 (2026): Jurnal Pharmascience
Publisher : Universitas Lambung Mangkurat

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20527/jps.v13i1.24555

Abstract

This study aimed to identify the most potent CDK2 inhibitor among seven artemisinin derivatives and, critically, to elucidate its binding mechanism and compare its affinity with that of the natural ligand, ATP. Molecular docking was performed using AutoDock 4.2.6 toward inactive and active forms of CDK2. Ligands were optimized using the Hartree-Fock method basis set 6-311G. Blind docking on the active form was used to determine the inhibition mechanism, employing the free energy of binding (ΔG) and dissociation constant (Ki) as affinity markers. Artesunate was the most potent derivative, exhibiting the highest affinity towards the active CDK2 form, with a ΔG of -11.7 kcal/mol and a Ki of 2.66 nM. Blind docking confirmed an ATP-competitive inhibition mechanism. Remarkably, Artesunate's Ki was significantly lower than that of ATP (8.73 nM). This enhanced affinity is attributed to specific interactions between the hemisuccinate side chain and the critical amino acid region, from 13-Gly to 16-Gly. Artesunate is suggested as a potent, ATP-competitive CDK2 inhibitor with an affinity exceeding that of ATP. These hypothesis-generating results suggest anticancer potential, yet require validation via MD or assays; limitations like scoring bias and protein flexibility necessitate cautious interpretation regarding the 13-Gly to 16-Gly target.
Co-Authors Daryono Hadi Tjahjono Evi Mulyani Kartawinata, Tutus Gusdinar Mohammad Rizki Fadhil Pratama Suratno Suratno